What Does Wall Street Think About Corcept Therapeutics (CORT)?

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best stocks to buy with over 50% upside potential. Canaccord Genuity analyst Edward Nash maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) on October 21, setting a $140 price target.

Similarly, H.C. Wainwright analyst Swayampakula Ramakanth also maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) on October 20, and set a $145 price target.

The analyst highlighted the potential of the company’s relacorilant for the treatment of ovarian cancer, stating that the recent ROSELLA trial data, that was presented at the European Society for Medical Oncology congress, reflected promising results for patients with platinum-resistant ovarian cancer previously treated with PARP inhibitors.

Although the subgroup typically has a poorer prognosis, it exhibited considerable progression-free survival benefits upon treatment with relacorilant in combination with nab-paclitaxel.

Ramakanth further stated that management is confident in the broader therapeutic potential of relacorilant, corroborated by the expansion of the BELLA Phase 2 trial to encompass additional indications such as endometrial cancer and platinum-sensitive ovarian cancer.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.